journal
MENU ▼
Read by QxMD icon Read
search

Annals of Hematology

journal
https://www.readbyqxmd.com/read/27915425/role-of-complexity-of-variant-philadelphia-chromosome-in-chronic-myeloid-leukemia-in-the-era-of-tyrosine-kinase-inhibitor-therapy
#1
LETTER
Zimu Gong, Lan Zheng, Zhenya Tang, Zi Chen, Wei Wang, Shi Bai, Guilin Tang, L Jeffrey Medeiros, Shimin Hu
No abstract text is available yet for this article.
December 3, 2016: Annals of Hematology
https://www.readbyqxmd.com/read/27913860/improved-clinical-outcomes-for-multiple-myeloma-patients-treated-at-a-single-specialty-clinic
#2
Ariana Berenson, Suzie Vardanyan, Michael David, James Wang, Nika Manik Harutyunyan, Jillian Gottlieb, Ran Halleluyan, Tanya M Spektor, Kyle A Udd, Shahrooz Eshaghian, Youram Nassir, Benjamin Eades, Regina Swift, James R Berenson
Despite recent advances made in its treatment, multiple myeloma (MM) remains an incurable B cell malignancy. Thus, the objective for treating these patients is to prolong overall survival (OS) and preserve patients' quality of life. We have analyzed data from 264 consecutive MM patients who had their initial visit between July 1, 2004 and December 1, 2014 and have received treatment in a single clinic specializing in MM. We determined their progression-free survival (PFS, OS, and 5-year OS). The PFS for frontline (n = 165 treatments), salvage (n = 980), and all treatments (n = 1145) were 13...
December 2, 2016: Annals of Hematology
https://www.readbyqxmd.com/read/27909887/similar-outcome-after-allogeneic-stem-cell-transplantation-with-a-modified-flamsa-conditioning-protocol-substituting-4%C3%A2-gy-tbi-with-treosulfan-in-an-elderly-population-with-high-risk-aml
#3
Udo Holtick, Marco Herling, Natali Pflug, Geothy Chakupurakal, Silke Leitzke, Dominik Wolf, Michael Hallek, Christof Scheid, Jens M Chemnitz
The fludarabine, amsacrine, and cytarabine (FLAMSA)-reduced-intensity conditioning (RIC) protocol has been described to be effective in patients with high-risk and refractory acute myeloic leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (aSCT). To increase safety and tolerability of the conditioning, we previously reported the feasibility to substitute the TBI component by treosulfan in elderly AML patients. We now present long-term follow-up data on patients treated with FLAMSA/treosulfan compared to the original FLAMSA/4Gy TBI protocol...
December 1, 2016: Annals of Hematology
https://www.readbyqxmd.com/read/27900446/health-related-quality-of-life-and-symptoms-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-treated-in-the-phase-iii-gadolin-study-with-obinutuzumab-plus-bendamustine-versus-bendamustine-alone
#4
Bruce D Cheson, Peter C Trask, John G Gribben, Natalie Dimier, Eva Kimby, Pieternella J Lugtenburg, Catherine Thieblemont, Elisabeth Wassner-Fritsch, Aino Launonen, Laurie H Sehn
We present health-related quality of life (HRQoL) data from GADOLIN, comparing bendamustine (B) alone or combined with obinutuzumab (G-B) in rituximab-refractory indolent non-Hodgkin lymphoma patients. The Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) questionnaire was administered on day 1 of cycles 1, 3, and 5 during treatment, at end of induction (EOI), bi-monthly for 2 years during maintenance/follow-up, and annually during extended follow-up until progression/death. Time to first ≥6-point worsening from baseline in the FACT-Lym trial outcome index (TOI) was estimated...
November 30, 2016: Annals of Hematology
https://www.readbyqxmd.com/read/27900452/microparticles-from-splenectomized-%C3%AE-thalassemia-hbe-patients-play-roles-on-procoagulant-activities-with-thrombotic-potential
#5
Phatchanat Klaihmon, Kunwadee Phongpao, Wasinee Kheansaard, Egarit Noulsri, Archrob Khuhapinant, Suthat Fucharoen, Noppawan Phumala Morales, Saovaros Svasti, Kovit Pattanapanyasat, Pornthip Chaichompoo
Thromboembolic events including cerebral thrombosis, deep vein thrombosis, and pulmonary embolism are major complications in β-thalassemia. Damaged red blood cells and chronic platelet activation in splenectomized β-thalassemia/HbE patients were associated with increased microparticles (MPs) releases into blood circulation. MPs are small membrane vesicles, which play important roles on coagulation. However, the role of MP in thalassemia is poorly understood. In this study, the effects of splenectomized-MPs on platelet activation and aggregation were investigated...
November 29, 2016: Annals of Hematology
https://www.readbyqxmd.com/read/27896415/predicting-risk-factors-for-varicella-zoster-virus-infection-and-postherpetic-neuralgia-after-hematopoietic-cell-transplantation-using-ordered-logistic-regression-analysis
#6
Yuko Kanbayashi, Yosuke Matsumoto, Junya Kuroda, Tsutomu Kobayashi, Shigeo Horiike, Toyoshi Hosokawa, Masafumi Taniwaki
To identify risk factors for varicella zoster virus (VZV) infection and postherpetic neuralgia (PHN) after hematopoietic cell transplantation (HCT), we conducted a retrospective chart review of 163 consecutive patients who underwent HCT between November 2004 and July 2014. Overall, the male/female (M/F) ratio was 80/83, median age at HCT was 54 (range 15-69) years, and autologous/allogeneic HCT (auto/allo-HCT) ratio was 71/92. Forty-four patients [M/F, 25/19; median age, 57 (range: 16-68) years; auto/allo-HCT, 26/18] developed VZV infection after HCT...
November 28, 2016: Annals of Hematology
https://www.readbyqxmd.com/read/27891555/the-epidemiologic-transition-of-thalassemia-and-associated-hemoglobinopathies-in-southern-taiwan
#7
Hui-Ching Wang, Li-Ling Hsieh, Yi-Chang Liu, Hui-Hua Hsiao, Shu-Kai Lin, Wen-Chan Tsai, Ta-Chih Liu
Since 1993, following the National Thalassemia Major Prevention Program and an increase in immigration and interracial marriages, especially in southern Taiwan, the distribution of hemoglobinopathies may have changed. This study investigates the epidemiologic transition of hemoglobinopathies. We analyzed 1870 specimens collected between 2003 and 2012 in southern Taiwan, used gap-polymerase chain reaction and PCR-restriction fragment length polymorphism-based methods, and confirmed genotypes of hemoglobinopathies by DNA sequencing...
November 28, 2016: Annals of Hematology
https://www.readbyqxmd.com/read/27889820/ruxolitinib-in-clinical-practice-for-primary-and-secondary-myelofibrosis-an-analysis-of-safety-and-efficacy-of-gruppo-laziale-of-ph-negative-mpn
#8
Massimo Breccia, Alessandro Andriani, Marco Montanaro, Elisabetta Abruzzese, Francesco Buccisano, Michele Cedrone, Antonietta Centra, Nicoletta Villivà, Francesca Celesti, Malgorzata Monica Trawinska, Fulvio Massaro, Ambra Di Veroli, Barbara Anaclerico, Gioia Colafigli, Matteo Molica, Antonio Spadea, Luca Petriccione, Giuseppe Cimino, Roberto Latagliata
Ruxolitinib, a JAK1 and JAK2 inhibitor, has been tested and approved for the treatment of primary and secondary myelofibrosis (MF). Aim of our study is to report safety and efficacy of ruxolitinib in 98 patients affected by MF treated outside clinical trials and collected and treated consecutively by the Lazio Cooperative Group for Ph negative myeloproliferative diseases.There were 45 males and 53 females; median age was 61.8 years (range 35.3-88). Forty-five patients were diagnosed as primary MF and 53 as secondary MF...
November 26, 2016: Annals of Hematology
https://www.readbyqxmd.com/read/27864605/erratum-to-bcr-abl-positive-acute-myeloid-leukemia-about-one-case-treated-with-ponatinib
#9
Maël Heiblig, Audrey Bidet, Evelyne Callet-Bauchu, Pierre-Yves Dumas, Kaddour Chabane, Gilles Salles, Arnaud Pigneux
No abstract text is available yet for this article.
November 19, 2016: Annals of Hematology
https://www.readbyqxmd.com/read/27864604/the-long-term-outcome-of-reduced-intensity-allogeneic-stem-cell-transplantation-from-a-matched-related-or-unrelated-donor-or-haploidentical-family-donor-in-patients-with-leukemia-a-retrospective-analysis-of-data-from-the-china-ric-cooperative-group
#10
Chang-Lin Yu, Zheng-Dong, Zhen-Hua Qiao, Jian-Min Wang, Huang-He, Ying-Min Liang, De-Pei Wu, Bao-An Chen, Bai-Hai, Bao-Fu Shi, Wan-Jun Sun, Jun-Xiao Qiao, Mei Guo, Jian-Hui Qiao, Qi-Yun Sun, Kai-Xun Hu, Ya-Jing Huang, Hong-Li Zuo, Xiao-Jun Huang, Hui-Sheng Ai
This study compared 6-year follow-up data from patients undergoing reduced-intensity conditioning (RIC) transplantation with an HLA-matched related donor (MRD), an HLA-matched unrelated donor (MUD), or an HLA-haploidentical donor (HID) for leukemia. Four hundred and twenty-seven patients from the China RIC Cooperative Group were enrolled, including 301 in the MRD, 79 in the HID, and 47 in the MUD groups. The conditioning regimen involved fludarabine combined with anti-lymphocyte globulin and cyclophosphamide...
November 18, 2016: Annals of Hematology
https://www.readbyqxmd.com/read/27864603/presence-of-risk-factors-does-not-affect-outcome-in-early-stage-pediatric-hodgkin-lymphoma-treated-with-abvd
#11
LETTER
Sainath Bhethanabhotla, Sameer Bakhshi
No abstract text is available yet for this article.
November 18, 2016: Annals of Hematology
https://www.readbyqxmd.com/read/27858107/gemcitabine-dexamethasone-and-cisplatin-gdp-as-salvage-chemotherapy-for-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphoma-not-otherwise-specified
#12
Fei Qi, Mei Dong, Xiaohui He, Yexiong Li, Weihu Wang, Peng Liu, Jianliang Yang, Lin Gui, Changgong Zhang, Sheng Yang, Shengyu Zhou, Yuankai Shi
Standard therapeutic options for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified (PTCL-NOS) remain unclear. There are few large cohort studies specifically focused on gemcitabine-based chemotherapy for PTCL-NOS. We retrospectively reviewed patients with relapsed or refractory PTCL-NOS who received salvage GDP (gemcitabine, dexamethasone, and cisplatin) chemotherapy at the Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China, from May 2008 to August 2014...
November 17, 2016: Annals of Hematology
https://www.readbyqxmd.com/read/27853835/potential-value-of-fdg-pet-ct-in-diagnosis-and-follow-up-of-tafro-syndrome
#13
LETTER
Fatemeh Behnia, Saeed Elojeimy, Manuela Matesan, David C Fajgenbaum
No abstract text is available yet for this article.
November 16, 2016: Annals of Hematology
https://www.readbyqxmd.com/read/27844105/reversion-of-serum-vzv-igg-antibody-preceding-disseminated-visceral-varicella-zoster-after-hematopoietic-stem-cell-transplantation
#14
LETTER
Sayaka Arakawa, Hidenori Kage, Haruka Chino, Munetoshi Hinata, Akimasa Hayashi, Takashi Toya, Satoshi Noguchi, Tetsuo Ushiku, Yasuhiro Yamauchi, Mineo Kurokawa, Masashi Fukayama, Takahide Nagase
No abstract text is available yet for this article.
November 14, 2016: Annals of Hematology
https://www.readbyqxmd.com/read/27838775/intravascular-lymphoma-look-through-the-small-vessels
#15
LETTER
Concepción Prats-Martín, Emilio Franco-Macías, Rosario M Morales-Camacho, Olga Pérez, M Teresa Vargas, Fátima de la Cruz Vicente, Juan J Borrero, Ricardo Bernal, José A Pérez-Simón
No abstract text is available yet for this article.
November 12, 2016: Annals of Hematology
https://www.readbyqxmd.com/read/27838774/radiologic-and-molecular-remission-of-follicular-t-cell-lymphoma-treated-with-lenalidomide
#16
LETTER
Yok-Lam Kwong
No abstract text is available yet for this article.
November 12, 2016: Annals of Hematology
https://www.readbyqxmd.com/read/27838773/role-of-reduced-intensity-conditioning-allogeneic-hematopoietic-cell-transplantation-in-older-patients-with-de-novo-acute-myeloid-leukemia
#17
Satoshi Yamasaki, Akihiro Hirakawa, Jun Aoki, Naoyuki Uchida, Takahiro Fukuda, Hiroyasu Ogawa, Kazuteru Ohashi, Tadakazu Kondo, Tetsuya Eto, Heiwa Kanamori, Hirokazu Okumura, Koji Iwato, Tatsuo Ichinohe, Junya Kanda, Makoto Onizuka, Yachiyo Kuwatsuka, Masamitsu Yanada, Yoshiko Atsuta, Akiyoshi Takami, Shingo Yano
Reduced-intensity conditioning (RIC) regimens extend the therapeutic use of allogeneic hematopoietic cell transplantation (HCT) to older patients. The survival trend in 2325 patients aged >50 years presenting with de novo acute myeloid leukemia (AML) who underwent first reduced-intensity HCT (RIC-HCT) was assessed by retrospectively analyzing outcomes between 2000 and 2013. The annual number of RIC-HCTs in Japan was higher in the 2008-2013 period (n = 205/year [1229/6 years]) than in the 2000-2007 period (n = 137/year [1096/8 years])...
November 12, 2016: Annals of Hematology
https://www.readbyqxmd.com/read/27837251/mcm7-polymorphisms-associated-with-the-aml-relapse-and-overall-survival
#18
Jin Sol Lee, Hyun Sub Cheong, Youngil Koh, Kwang-Sung Ahn, Hyoung Doo Shin, Sung-Soo Yoon
The minichromosome maintenance complex component 7 (MCM7) encodes a member of MCM complex, which plays a critical role in the initiation of gene replication. Due to the importance of MCM complex, MCM7 gene has been regarded as a candidate gene for cancer development. In the present study, seven MCM7 polymorphisms were genotyped in 344 subjects composed of 103 acute myeloid leukemia (AML) patients and 241 normal controls to examine the possible associations between MCM7 polymorphisms and the risk of AML. MCM7 polymorphisms were not associated with the risk of AML (P > 0...
November 12, 2016: Annals of Hematology
https://www.readbyqxmd.com/read/27837250/development-of-a-disease-specific-quality-of-life-questionnaire-for-patients-with-aplastic-anemia-and-or-paroxysmal-nocturnal-hemoglobinuria-qlq-aa-pnh-report-on-phases-i-and-ii
#19
Martha Groth, Susanne Singer, Cathrin Niedeggen, Andrea Petermann-Meyer, Alexander Röth, Hubert Schrezenmeier, Britta Höchsmann, Tim H Brümmendorf, Jens Panse
Acquired aplastic anemia (AA) and paroxysmal nocturnal hemoglobinuria (PNH) are interrelated ultra-rare diseases. Quality of life (QoL) evaluation tools used in studies for AA and PNH are unspecific and designed for cancer patients (e.g., the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, EORTC QLQ-C30). Given the complexity of AA and PNH, variation in symptoms and treatments, younger age of many patients, and the fact that AA and PNH are not classified as malignant diseases, it is likely that cancer-specific questionnaires are inappropriate...
November 11, 2016: Annals of Hematology
https://www.readbyqxmd.com/read/27822611/rivaroxaban-for-heparin-induced-thrombocytopenia-adding-to-the-evidence
#20
LETTER
Shin Yeu Ong, Yun Ann Chin, Hein Than, Chuen Wen Tan, Eng Soo Yap, Wan Hui Wong, Heng Joo Ng
No abstract text is available yet for this article.
November 7, 2016: Annals of Hematology
journal
journal
30731
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"